Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

Officials of the V.I. Port Authority held a double celebration at the Cyril E. King Airport Thursday: the completion of a new ...

As Ripple (XRP) looks to make a comeback, Mutuum Finance (MUTM) is rapidly emerging as a formidable performer in the crypto ...

The Grand Sierra Resort Arena project has had many twists and turns since it was announced 19 months ago but an end — or at ...

Having worked on the three-man defence in training for some time, AC Milan’s first three games have yielded some positive ...

It is the UCL semifinals as we continue our Champions League odds series with a Barcelona-Inter Milan prediction and pick.

The first leg of the UCL Semi-Finals is on tap as we continue our Champions League odds series with an Arsenal-PSG prediction ...

In May 2025, if ADA can maintain support around $0.67 and decisively break above the key resistance at $0.74, a move toward ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

The Trump administration paused construction of the controversial project — 54 turbines in the Atlantic Ocean off Long Island ...